Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2018 · 10-Q
Revenue$0.00$0.00— vs Q1 2017 Net Income-$10.09M-$10.09MN/M vs Q1 2017 EPS Diluted-$0.20-$0.20N/M vs Q1 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
-$7,160,000
N/M
Operating Cash Flow-$4,226,000N/M Free Cash Flowderived-$4,228,000N/M ended Mar 31, 2018 · filed May 15, 2018 · 45 d after period end